OPTHEA LIMITED (OPT)

Latest AI Signal: BUY
Status: NEW
Days Old: 0

Confidence: 65%

Date: 21-05-2026

Price: $0.600

Last Price: $0.600

Latest  OPTHEA LIMITED(OPT)   News

26 Jul 2023, 08:00 PM

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the American Medical Association’s Unit

24 Jul 2023, 08:00 PM

Opthea to Present at the 2023 Ophthalmology Innovation Summit

Opthea Limited MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief

13 Jul 2023, 08:00 PM

Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting

Opthea Limited Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseases Participation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD hosted by Oppenheimer & Co. MELBOURNE, Australia, July 13, 2023 (GLOBE NEWSWIRE) --

10 Jul 2023, 08:00 PM

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

Opthea Limited MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today  the  resignation of Dr. Joel Naor, Chief Me

08 Jun 2023, 08:00 PM

Opthea Appoints Anshul Thakral as Non-Executive Director of the Board

Opthea Limited MELBOURNE, Australia, June 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral

Chart available once enough post-signal price data is available.

BUY Confidence Medium

AI Confidence - 65 % model confidence

Business Overview

Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal vascular diseases, including wet age-related macular degeneration (AMD). The company leverages its proprietary Angiogenesis Modulation Platform to develop treatments aimed at improving patient outcomes in a competitive ophthalmology market dominated by established players.

Financial Analysis

Cash Flow	Weak
Debt	Low
Profitability	Weak
Revenue Trend	Downtrend

Technical Analysis

Trend	Bullish
Momentum	Moderate
RSI Signal	Neutral
Support Level	$ 0.55
Resistance Level	$ 0.65

Valuation

Valuation - Undervalued

The stock is trading below its recent highs with significant upside potential given upcoming clinical milestones and limited current revenue.

Catalysts

• Upcoming Phase 2b clinical trial results expected to validate efficacy.

• Potential partnerships or licensing deals with larger pharmaceutical companies.

Recommendation

Action - Buy

Timeframe - Medium Term

Opthea presents a compelling risk-reward profile with promising clinical assets in a high-value ophthalmology market. While financials are currently weak, upcoming trial data and strategic partnerships could drive significant share price appreciation.